AN2 Therapeutics (ANTX) Cash from Investing Activities (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Cash from Investing Activities data on file, last reported at $8.3 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $8.3 million, down 9.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $27.4 million (down 26.9% YoY), and the FY2025 annual result was $28.3 million, down 48.14% from the prior year.
• Cash from Investing Activities grew to $8.3 million in Q1 2026 per ANTX's latest filing, from $7.2 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $26.3 million in Q1 2024 and troughed at -$62.5 million in Q3 2023.
• A 5-year average of $1.5 million and a median of $7.2 million in 2025 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities slumped 2595.81% in 2023, then jumped 204.27% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at $6.1 million in 2022, then plunged by 93.06% to $420000.0 in 2023, then sank by 1738.1% to -$6.9 million in 2024, then jumped by 204.27% to $7.2 million in 2025, then advanced by 15.56% to $8.3 million in 2026.
• Business Quant data shows ANTX's Cash from Investing Activities at $8.3 million in Q1 2026, $7.2 million in Q4 2025, and $6.1 million in Q3 2025.